Work

Tocilizumab and Ocrelizumab-related reactions in patients with rare diseases – an analysis of spontaneous reports using the EudraVigilance database

Year: 2025

Type: conference-paper

Abstract: Background: In recent years, several advanced disease-modifying drugs (DMDs) have been approved for the treatment of rare autoimmune disorders. However, data on the safety and effectiveness of these novel DMDs outside the pivotal trials is limited. Hence, the CONTRIBUTE project aims to assess the effectiveness [for full text, please go to the a.m. URL]

Source: German Medical Science (German Research Foundation)

DOI: 10.3205/25gaa08

Authors: Himmel, Julian, Rottenkolber, Marietta, Hellwig, Kerstin, Kiltz, Uta, Schmiedl, Sven

Institutions: Witten/Herdecke University, Institut für Allgemeinmedizin, Ludwig-Maximilians-Universität München, St. Josef-Hospital, Ruhr University Bochum, Rheumazentrum Ruhrgebiet

Language: English

Topic: Pharmacovigilance and Adverse Drug Reactions

Subfield: Toxicology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: Gemeinsame Bundesausschuss